SCOUT-HCM data show LVOT gradient reductions persisted, patients switching from placebo responded similarly, and no patient had LVEF below 50%.
|Articles|June 21, 2023
5 Key Sessions and Interviews at McKesson ideaShare 2023
Author(s)Ashley Gallagher, Editor
McKesson ideaShare is held from June 22 to June 25 in Las Vegas, Nevada.
Advertisement
Pharmacy Times® will be covering the
McKesson’s ideaShare will also be providing continuing education courses for attendees with up to 10 hours of credit.
Stay tuned on
- An interview with Nancy Lyons, BSPharm, MBA, CDCES, vice president and chief pharmacy officer at Health Mart, a part of McKesson Corporation, who will be discussing how pharmacy technicians can expand their role in community pharmacy. She will discuss how technicians can complete a community health worker certification.
- A session about public policy presented by McKesson policy experts and industry advocates who work together to elevate the role of the pharmacist in their community. Experts will recap some of the major events in public policy that happened in 2022 and inform pharmacists about exciting new initiatives and updates that can be expected in the coming year.
- An interview with Crystal Lennartz, vice president and general manager of Health Mart Atlas & Atlas Specialty, who will discuss how pharmacies can start to prepare for direct and indirect remuneration (DIR) changes in 2024. She will also be discussing how Health Mart Atlas DIR Assist can help pharmacies prepare.
- An educational discussion about the important and growing role of the pharmacy technician. The educational session will explain how technicians can contribute more to the pharmacy team when they receive community health worker (CHW) training, the growing impact they can have on their community as an advocate, and it will inform what is required to receive CHW training.
- An interview with Brittany Hoffman-Eubanks, PharmD, MBA, senior manager of Clinical Pharmacy Oversight at Health Mart, who will be discussing the impact of pharmacy-based COVID-19 vaccines. She will be discussing the roll community pharmacies played, the impact it had on underserved populations, and the momentum for the continued evolutions of pharmacy.
Follow Pharmacy Times for coverage of the conference on our website and on social media for the latest updates.
Advertisement
Related to this article
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
At SITC 2026, 10 of 15 patients with advanced melanoma responded to investigational amsokigene autoleucel at the recommended phase 2 dose, with 5 still in response 12 months after infusion.
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
If gene therapies are expected to deliver decades of benefit, long-term evidence collection must be coordinated, useful to patients, and financially sustainable.
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
2
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
3
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
4
Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care
5